摘要
随着分子靶向药物的研发和临床应用,肿瘤的分子靶向治疗已成为肿瘤内科的研究热点。现有的研究结果已表明,肿瘤分子靶向治疗具有较好的安全性和有效性,尤其以多靶点Raf激酶抑制剂,表皮生长因子受体(EGFR)和血管内皮生长因子受体(VEGF)为靶点的治疗药物,已在临床中取得较好的疗效。本文就这几种治疗中具有代表性的药物进行综述,并提出今后的分子靶向治疗可能发展的方向。
With the research and clinical use of molecular targeted drugs, the molecular-targeted tumor medical treatment of tumors has become more popular. Tumor molecular-targeted therapies have been demostrated safe and effective, particularly in the multi-target Raf kinase inhibitor, epidermal growth factor receptor （EGFR）, and vascular endothelial growth factor receptor （VEGF） -targeted drugs. This review illuminated the feature of these types of target therapeutic drugs and proposed future development of molecularly targeted therapy.
出处
《癌症进展》
2008年第3期293-298,292,共7页
Oncology Progress
基金
国家自然科学基金(30600729)
北京协和医院青年基金(2005 37A)
CMB项目:No.06837资助下完成
